Argatroban, Rt-PA Clinical Trial
Official title:
Argatroban Plus R-tPA for Acute Posterior Circulation Infarction (AR-PCI): a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study
Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of
morbidity, mortality and disability. A large number of studies have confirmed that the
thrombolytic therapy can effectively open blood vessels and improve the functional prognosis
of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment
to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients
receiving thrombolysis will have good prognosis, while a large number of patients will still
be disabled and even dead. How to improve the neurofunction prognosis of thrombolytic
patients has been a hot topic in the world.
Recent studies have found that the combined application of argatroban and rt-PA in the
treatment of acute anterior circulation infarction might improve the clinical prognosis and
not significantly increase bleeding. Some studies have reported that the combined application
of argatroban and rt-PA could improve the blood vessel opening rate, and prevent re-occlusion
after opening.
Based on the discussion, the present study is designed to explore the efficacy and safety of
argatroban plus rt-PA in the treatment of acute posterior circulation infarction.
n/a